PEDRO MORANTE: Open Payments
NPI 1689038507 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,235 in 38 payments from 8 companies in 2025. Trend: 2023 $651 · 2024 $685 · 2025 $1,235
Food & beverage: $1,235
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 15 | $373 |
| Janssen Pharmaceuticals, Inc | 6 | $241 |
| ABBVIE INC. | 11 | $202 |
| Neurocrine BioSciences, Inc. | 2 | $149 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $122 |
| Vanda Pharmaceuticals Inc. | 1 | $112 |
| Lundbeck LLC | 1 | $19 |
| Tris Pharma Inc | 1 | $17 |
Products named: ARISTADA, INVEGA SUSTENNA, VRAYLAR, INGREZZA, CAPLYTA, FANAPT, REXULTI, Dyanavel XR.
Industry payments across CA — which companies pay providers there.
